Shares of Kala Bio Inc. tumbled over 35% on Wednesday, on track for their worst single-day decline ever, after the company ...

ARLINGTON, Mass. - KALA BIO, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on developing treatments for rare and severe eye diseases, announced a change in its executive leadership on Monday ...

KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...

The rationale for the study was anecdotal reports of the effects of breast milk used by mothers to treat blocked tear ducts, ...

KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and ...

Dry eyes are associated with minute punctate epithelial erosions of the cornea, usually detected by fluorescein or Rose Bengal staining of the ocular surface. This is seen in post-LASIK patients ...

Patients with limbal deficiency may benefit from limbal stem cell transplantation to alleviate persistent epithelial defects, maintain conjunctivalization regression and corneal avascularity ...